Downregulation of α‐synuclein in a mouse model of Alzheimer’s Disease: neuropathological, behavioral and transcriptomic changes
Collectively, our data supports the use of ApoB<sup>11</sup>:ASO α-syn conjugates delivered systemically to downregulate α-syn as a promising future therapeutic strategy in AD. Our work suggests that knocking down α-syn could be necessary to prevent neuropathology in AD.
Authors
- Robert A. Rissman (ORCID: https://orcid.org/0000-0001-9245-8278)
- André Leitão (ORCID: https://orcid.org/0000-0003-0500-3545)
- Chengbiao Wu (ORCID: https://orcid.org/0000-0002-3660-088X)
- Rijwan Uddin Ahammad
- Brian Spencer (ORCID: https://orcid.org/0000-0002-7486-1941)
Institutions
- University of Southern California (US)
- Autism Research Institute (US)
- University of California San Diego (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.092752
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00